EGFR and breast carcinoma: Human epidermal growth factor receptor 3 (HER3), a member of the epidermal growth factor receptor (EGFR) family, has been associated with poor clinical outcomes and resistance to targeted therapies in various cancers, including breast cancer [15–19].